



PRESS RELEASE

SGD Pharma's latest annual sustainability report details global environmental, social and ethical efforts

Paris La Défense, FRANCE – 26 June 2023: Global market leader in molded glass packaging solutions for the pharmaceutical industry, SGD Pharma, has published its latest Corporate Social Responsibility (CSR) Report 2022 to underscore its company-wide commitment to a green and sustainable present and future. The 2022 Report is published soon after the company received its coveted ECOVADIS Gold award, achieving its highest ever score of 75 out of 100 - the company is currently rated in the top 2% of global companies in the 'Manufacture of glass and glass products' category.

Key achievements include:

- 100% of all SGD Pharma owned glass manufacturing plants are ISO 45001 certified
- 100% of SGD Pharma sites are certified with ISO 14001
- 100% of critical suppliers have CSR clauses in their contracts
- 99.5% of our internal cullet is reused in our production process
- >20% reduction in water consumption vs 2020
- 86% EHS Maturity Matrix

The company-wide focus on CSR under new CEO Olivier Rousseau and with new investors PAI Partners on board means stretch targets have been set ahead:

- Halve Scope 1 and Scope 2 emissions by 2030
- 35% reduction in carbon footprint by 2030
- 65% reduction in carbon footprint by 2040 (compared with 2020 baseline)
- Goal: Zero accidents
- Reduction of 65% of absolute CO₂ emissions by 2024, (consisting of 52% decrease in CO₂ emissions / melted tons and Zero net CO₂ emissions)

As a global leader in heavy manufacturing of pharmaceutical-grade glass, SGD Pharma takes its global and local responsibilities seriously. Each location has an energized CSR plan deployed locally, and conforms to the company's overall standards.

The company has made significant BAT (best available technology) investment in its global plants and infrastructure as part of a continual search for improvements in energy consumption. This includes furnaces renovations and updated glass production facilities in all 5 plants, including furnace 2 in Sucy-en-Brie, France (leading to a reduction of more than 10% in CO₂ and Nox emissions) and Saint-Quentin-La-Motte, France, which has both a full electrical furnace and a second oxy-fuel combustion furnace equipped with electrical boosting, both of which allow the plant to produce glass with low carbon emissions. SGD Pharma has also committed to uplift its decarbonization investment by 20% over the coming 15 years.

CSR Spotlight: SGD Pharma Zhanjiang China – planting mangroves

As well as being SA 8000 certified, the SGD Pharma China plant in Zhanjiang supports the local community with its local footprint, relationships with local government and with local



PRESS RELEASE

institutions, local hiring policies and by helping to protect biodiversity in Zhanjiang. The city is home to one of the world's most successful examples of wetland ecological restoration and SGD Pharma has committed to supporting the community's efforts to tackle deforestation by planting mangrove trees. By the end of 2022, SGD Pharma planted a total of 1000 mangroves trees on the coast of Zhanjiang, China, in association with Zhanjiang Nature and Resource Bureau.

During a visit to the SGD Pharma Zhanjiang site in April 2023, Zhanjiang Mayor Mr. Zeng Jinze (曾进泽) and a delegation joined CEO Olivier Rousseau, COO Christophe Muguet, and the local team at SGD Pharma China, to plant new mangrove roots. The Mayor stressed the importance of mangrove preservation for Zhanjiang and the many benefits it brings to society in terms of biodiversity, carbon sync and protection of the coast. SGD Pharma is proud to contribute to biodiversity and hopes to continue its biodiversity projects in China and other plants during 2023. A further 300 trees have been planted.

For more information on SGD Pharma's sustainable actions and to read the 2022 report visit: <https://www.sgd-pharma.com/sustainability-0>

ENDS

About SGD Pharma

SGD Pharma is a global producer of molded and tubular glass for pharmaceutical primary packaging. Building on over a century of expertise, we provide exceptional quality packaging solutions dedicated to parenteral, oral, and nasal products for every therapeutic application. Our worldwide clients are supported by more than 90 agents and distributors and benefit from ongoing innovation at our five best-in-class ISO 15378 certified, GMP compliant manufacturing plants, giving a truly global supply chain infrastructure.

Marketing & Communication SGD Pharma

Jean-Pascal Marquié – jean-pascal.marquie@sgdgroup.com

The Scott Partnership

Alisha Mountford – sgdpharma@scottpr.com